Chengdu Baiyu Jingelai Pharmaceutical

Chengdu Baiyu Jingelai Pharmaceutical is a specialized biopharmaceutical subsidiary of Chengdu Baiyu Pharmaceutical, based in Chengdu, China. The company serves as a primary research and development arm for the parent group, focusing on the discovery and clinical advancement of innovative small molecule therapeutics. Its core pipeline is centered on oncology, with lead candidates targeting DNA damage repair and kinase signaling pathways. Notable programs include BY101921, a PARP inhibitor currently in Phase 2 clinical trials, and BY101911, a multi-target EGFR inhibitor. The company leverages integrated R&D facilities to transition candidates from early-stage discovery through to late-stage clinical development.